<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3488">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01376089</url>
  </required_header>
  <id_info>
    <org_study_id>GE-012-097</org_study_id>
    <nct_id>NCT01376089</nct_id>
  </id_info>
  <brief_title>Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis</brief_title>
  <official_title>A Phase 4 Randomized, Double-blind Study Comparing Patient Comfort and Safety Between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>i3 Statprobe</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GE Healthcare</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate and compare overall patient comfort profile between
      the Iso-osmolar contrast media (IOCM), iodixanol 320 mg I/mL, and a Low-osmolar contrast
      media (LOCM), iopamidol 370 mg I/mL in patients undergoing Contrast-Enhanced Computed
      Tomographic (CECT) imaging of the abdomen/pelvis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>Frequency of Subjects With Moderate/Severe Discomfort When Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis.</measure>
    <time_frame>Within 10 minutes post contrast administration</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of subjects experiencing any moderate (score of 4 - 7) to severe (score 8 - 10) discomfort for cold or heat or pain between Iodixanol and Iopamidol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Subjects With Moderate / Severe Discomfort When Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis.</measure>
    <time_frame>Within 10 minutes post contrast administration.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of subjects experiencing moderate (score of 4 -7) to severe (score of 8 - 10) discomfort for cold, heat or pain between Iodixanol and Iopamidol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Overall Image Quality Between Iodixanol and Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis.</measure>
    <time_frame>Ten minutes post contrast administration.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall Image Quality rated as 'Excellent, Adequate or Poor' by radiologists blinded to the contrast administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">304</enrollment>
  <condition>Patient Comfort and Safety</condition>
  <arm_group>
    <arm_group_label>Arm 1-Iodixanol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2-Iopamidol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iodixanol</intervention_name>
    <description>Iodixanol 320 mg I/mL as a single iv. administration.</description>
    <arm_group_label>Arm 1-Iodixanol</arm_group_label>
    <other_name>Visipaque</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iopamidol</intervention_name>
    <description>Comparator agent iopamidol (Isovue) 370 mg I/mL as a single iv. administration.</description>
    <arm_group_label>Arm 2-Iopamidol</arm_group_label>
    <other_name>Isovue</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is over 18 years old.

          -  Subjects are referred to undergo a CECT imaging of the abdomen/pelvis as part of
             their routine clinical care.

        Exclusion Criteria:

          -  The subject has known allergies to iodine or any prior history of adverse reaction to
             iodinated CM.

          -  The subject received another administration of CM within 24 hours prior to baseline
             or is scheduled to receive one within the 24 hour follow-up period.

          -  The subject is pregnant.

          -  The subject is taking metformin (e.g., Glucophage®) but is not willing or unable to
             discontinue at the time of the study procedure.

          -  The subject manifests thyrotoxicosis or is on dialysis.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren Lim, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>GE Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GE Healthcare</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 5, 2013</lastchanged_date>
  <firstreceived_date>June 16, 2011</firstreceived_date>
  <firstreceived_results_date>May 30, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Iodixanol</mesh_term>
    <mesh_term>Iopamidol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 304 subjects were enrolled in this study, however, 5 subjects did not receive contrast media due to administrative and /or technical reason leaving 299 subjects included in the analysis.</recruitment_details>
      <pre_assignment_details>A total of 304 subjects were enrolled in this study, however, 5 subjects did not receive contrast media due to administrative and /or technical reason leaving 299 subjects included in the analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1-Iodixanol</title>
          <description>Subjects were injected with Iodixanol (Visipaque).</description>
        </group>
        <group group_id="P2">
          <title>Arm 2-Iopamidol</title>
          <description>Subjects were injected with Iopamidol (Isovue).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient received no contrast media</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1-Iodixanol</title>
        </group>
        <group group_id="B2">
          <title>Arm 2-Iopamidol</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="151"/>
                <measurement group_id="B2" value="148"/>
                <measurement group_id="B3" value="299"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="91"/>
                <measurement group_id="B2" value="91"/>
                <measurement group_id="B3" value="182"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
                <measurement group_id="B2" value="57"/>
                <measurement group_id="B3" value="117"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="57.8" spread="15.23"/>
                <measurement group_id="B2" value="58.5" spread="15.02"/>
                <measurement group_id="B3" value="58.1" spread="15.10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="68"/>
                <measurement group_id="B2" value="80"/>
                <measurement group_id="B3" value="148"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="83"/>
                <measurement group_id="B2" value="68"/>
                <measurement group_id="B3" value="151"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="65"/>
                <measurement group_id="B2" value="62"/>
                <measurement group_id="B3" value="127"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Germany</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="45"/>
                <measurement group_id="B2" value="43"/>
                <measurement group_id="B3" value="88"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Spain</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="70"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>United Kingdom</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Subjects With Moderate/Severe Discomfort When Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis.</title>
        <description>Number of subjects experiencing any moderate (score of 4 - 7) to severe (score 8 - 10) discomfort for cold or heat or pain between Iodixanol and Iopamidol.</description>
        <time_frame>Within 10 minutes post contrast administration</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-Iodixanol (Visipaque)</title>
            <description>Subjects injected with Visipaque contrast media. Number of subjects with any Moderate / Severe discomfort.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2-Iopamidol (Isovue)</title>
            <description>Subjects injected with Isovue contrast media. Number of subjects with any Moderate / Severe discomfort.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="151"/>
                  <measurement group_id="O2" value="147"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Frequency of Subjects With Moderate/Severe Discomfort When Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis.</title>
            <description>Number of subjects experiencing any moderate (score of 4 - 7) to severe (score 8 - 10) discomfort for cold or heat or pain between Iodixanol and Iopamidol.</description>
            <units>Number of Subjects with discomfort</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="53" lower_limit="27.49" upper_limit="42.71"/>
                  <measurement group_id="O2" value="99" lower_limit="59.77" upper_limit="74.93"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Subjects With Moderate / Severe Discomfort When Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis.</title>
        <description>Number of subjects experiencing moderate (score of 4 -7) to severe (score of 8 - 10) discomfort for cold, heat or pain between Iodixanol and Iopamidol.</description>
        <time_frame>Within 10 minutes post contrast administration.</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-Iodixanol (Visipaque 320mgI/mL)</title>
            <description>Subjects injected with Visipaque 320mgI/mL contrast media. Number of subjects with any Moderate / Severe discomfort.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2-Iopamidol (Isovue 370mgI/mL)</title>
            <description>Subjects injected with Isovue 370mgI/mL contrast media. Number of subjects with any Moderate / Severe discomfort.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="151"/>
                  <measurement group_id="O2" value="147"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Frequency of Subjects With Moderate / Severe Discomfort When Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis.</title>
            <description>Number of subjects experiencing moderate (score of 4 -7) to severe (score of 8 - 10) discomfort for cold, heat or pain between Iodixanol and Iopamidol.</description>
            <units>Number of Subjects with discomfort</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Discomfort of Cold</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5" lower_limit="0.46" upper_limit="6.17"/>
                  <measurement group_id="O2" value="11" lower_limit="3.23" upper_limit="11.74"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Discomfort of Heat</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45" lower_limit="22.51" upper_limit="37.10"/>
                  <measurement group_id="O2" value="94" lower_limit="56.18" upper_limit="71.71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Discomfort of Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5" lower_limit="0.46" upper_limit="6.17"/>
                  <measurement group_id="O2" value="3" lower_limit="0.00" upper_limit="4.33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Overall Image Quality Between Iodixanol and Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis.</title>
        <description>Overall Image Quality rated as ‘Excellent, Adequate or Poor’ by radiologists blinded to the contrast administration.</description>
        <time_frame>Ten minutes post contrast administration.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-Iodixanol (Visipaque 320mgI/mL)</title>
            <description>Subjects injected with Visipaque 320mgI/mL contrast media.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2-Iopamidol (Isovue 370mgI/mL)</title>
            <description>Subject injected with Isovue 370mgI/mL contrast media.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="151"/>
                  <measurement group_id="O2" value="148"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Comparison of Overall Image Quality Between Iodixanol and Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis.</title>
            <description>Overall Image Quality rated as ‘Excellent, Adequate or Poor’ by radiologists blinded to the contrast administration.</description>
            <units>Number of subject images</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Image Quality was Excellent</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="144"/>
                  <measurement group_id="O2" value="133"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Image Quality was Adequate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Image Quality was Poor</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1-Iodixanol (Visipaque 320mgI/mL)</title>
          <description>Subjects injected with Visipaque 320mgI/mL contrast media.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2-Iopamidol (Isovue 370mgI/mL)</title>
          <description>Subject injected with Isovue 370mgI/mL contrast media.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="151"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorder: Feeling Cold</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="151"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>General Disorders: Feeling Hot</sub_title>
                <counts group_id="E1" events="77" subjects_affected="77" subjects_at_risk="151"/>
                <counts group_id="E2" events="92" subjects_affected="92" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Administration Site Conditions: Injection Site Coldness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Administration Site Conditions: Injection Site Reaction</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="151"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="151"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lauren Lim, PharmD</name_or_title>
      <organization>GE Healthcare</organization>
      <phone>1-626-356-1937</phone>
      <email>lauren.lim@ge.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
